BioPharmSignal logoBioPharmSignal

Biotech News

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

Arvinas, Inc. (ARVN)Arvinas, Inc.Earnings

– First-ever FDA approved PROTAC supports the further development and potential of Arvinas’ pipeline – – Announced FDA Approval of VEPPANU ™ (vepdegestrant) for the treatment of ESR1m, ER+/HER2- advanced breast cancer – – Announced selection of Rigel Pharmaceuticals for the exclusive global rights

Related news

ARVNArvinas, Inc.2026-02-24 12:00 EST

Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

ARVNArvinas, Inc.2026-05-05 11:00 EST

Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026

PMVPPMV Pharmaceuticals2026-05-12 12:00 EST

PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights

EXELExelixis2026-05-05 20:05 EST

Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update

NRIXNurix Therapeutics2026-04-08 10:00 EST

Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

EXELExelixis2026-08-05 20:05 EST

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

NRIXNurix Therapeutics2026-07-09 20:01 EST

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

ZNTLZentalis2026-05-12 20:05 EST

Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

CCCCC4 Therapeutics2026-05-12 11:00 EST

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

BCRXBioCryst Pharmaceuticals2026-05-06 11:00 EST

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

View all latest news

Arvinas, Inc.

Arvinas is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

ARVNArvinas, Inc.2026-06-04 12:00 EST

Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease

ARVNArvinas, Inc.2026-05-29 20:01 EST

Arvinas to Present at Jefferies Global Healthcare Conference

ARVNArvinas, Inc.2026-05-18 14:30 EST

Arvinas Employees Give Back During Company-wide Impact Day

ARVNArvinas, Inc.2026-05-12 11:05 EST

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

ARVNArvinas, Inc.2026-05-12 11:00 EST

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

Stock data

Close
10.78 USD
Market cap
695.5M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States